Income statement
SEK
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 313M | 253M | 221M | 157M | 96M |
| Gross Profit | 4M | 175M | 146M | 101M | 65M |
| Operating Income | 4M | 34M | 13M | -1M | -11K |
| EBITDA | 28M | 50M | 31M | 14M | 3M |
| Net Income | -17M | 40M | 8M | -10M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.50
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Paxman AB (publ) (PXMBF) is a Healthcare stock with a market cap of $1.18B and listed on OTC. The stock last traded around $3.50 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +23.5%, EPS growth of -136.0%, a dividend yield of 0.0%. What stands out right now is revenue +23.5%, EPS -136.0%, free cash flow -153.0% with operating margin 1.5% and ROIC 1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 3.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PXMBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PXMBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PXMBF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PXMBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$96.2M
-38.6% YoY
FY Net Income
-$12.8M
-23.8% YoY
Free Cash Flow
-$27.9M
+15.4% YoY
Revenue Growth
+23.5%
EPS Growth
-136.0%
Gross Margin
47.7%
Net Margin
-5.1%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 313M | 253M | 221M | 157M | 96M |
| Gross Profit | 4M | 175M | 146M | 101M | 65M |
| Operating Income | 4M | 34M | 13M | -1M | -11K |
| EBITDA | 28M | 50M | 31M | 14M | 3M |
| Net Income | -17M | 40M | 8M | -10M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 121M | 40M | 25M | 38M | 72M |
| Total Assets | 478M | 227M | 167M | 174M | 166M |
| Total Liabilities | 74M | 63M | 45M | 60M | 41M |
| Shareholder Equity | 404M | 164M | 123M | 114M | 126M |
| Total Debt | 13M | 14M | 14M | 17M | 17M |
| Net Debt | -108M | -26M | -11M | -21M | -55M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-254.2% YoY
Capital Expenditures
24M
+33.3% YoY
Free Cash Flow
28M
+15.4% YoY
Key ratios
Gross Margin
47.7%
Operating Margin
1.5%
Net Margin
-5.1%
ROE
-4.2%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.